LP Pharma raised $30M in a B round led by state-owned SDIC Fund Management.
December 26, 2017 -- LP Pharmaceutical (Xiamen) raised $30 million in a B round led by state-owned SDIC Fund Management. LP focuses on developing drugs with mucosa/oral controlled delivery technology. The company, formed in 2012 by returnees, initially worked on two treatments, one for AIDS and the other an unspecified cancer indication. Joining the B round were CMB International Capital and Zhangzhou PienTzeHuang Pharma.
